UB Paderborn / Katalog / Suche / in CDI

Es ist ein Fehler in der Kommunikation mit einem externen System aufgetreten. Bitte versuchen Sie Ihre letzte Aktion erneut. Sollte der Fehler bestehen bleiben, setzen Sie sich bitte mit dem Informationszentrum der Bibliothek in Verbindung oder versuchen Sie es später erneut.

1 – 25 von 43

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors

The New England journal of medicine, 2015-01, Vol.372 (3), p.211-221

2015

Volltextzugriff (PDF)

Effects of Varespladib Methyl on Biomarkers and Major Cardiovascular Events in Acute Coronary Syndrome Patients

Journal of the American College of Cardiology, 2010-09, Vol.56 (14), p.1079-1088

2010

Volltextzugriff (PDF)

Nitric Oxide Negatively Regulates Mammalian Adult Neurogenesis

Proceedings of the National Academy of Sciences - PNAS, 2003-08, Vol.100 (16), p.9566-9571

2003

Volltextzugriff (PDF)

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

The Lancet (British edition), 2009-02, Vol.373 (9664), p.649-658

2009

Volltextzugriff (PDF)

Essential function of nitric oxide synthase in Drosophila

Current biology, 2004-10, Vol.14 (20), p.R881-R882

2004

Volltextzugriff (PDF)

Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2015-07, Vol.314 (2), p.151

2015

Volltextzugriff (PDF)

Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension

The Lancet (British edition), 2019-08, Vol.394 (10196), p.396-406

2019

Volltextzugriff (PDF)

The Drosophila Nitric-oxide Synthase Gene (dNOS) Encodes a Family of Proteins That Can Modulate NOS Activity by Acting as Dominant Negative Regulators

The Journal of biological chemistry, 2001-11, Vol.276 (45), p.42241-42251

2001

Volltextzugriff (PDF)

Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial

The Lancet (British edition), 2019-04, Vol.393 (10179), p.1417-1427

2019

Volltextzugriff (PDF)

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors

European journal of heart failure, 2015-10, Vol.17 (10), p.1057-1065

2015

Volltextzugriff (PDF)

Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD

Clinical journal of the American Society of Nephrology, 2018-01, Vol.13 (1), p.26-35

2018

Volltextzugriff (PDF)

Action of Veverimer on Gastrointestinal Acid Binding Is Not Affected by Omeprazole: PO2374

Journal of the American Society of Nephrology, 2020-10, Vol.31 (10S), p.721-722

2020

Volltextzugriff (PDF)

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia

Kidney international, 2015-12, Vol.88 (6), p.1427-1433

2015

Volltextzugriff (PDF)

noxin, a Novel Stress-Induced Gene Involved in Cell Cycle and Apoptosis

Molecular and Cellular Biology, 2007-08, Vol.27 (15), p.5430-5444

2007

Volltextzugriff (PDF)

Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis

Nephrology, dialysis, transplantation, 2023-05, Vol.38 (6), p.1448-1458

2023

Volltextzugriff (PDF)

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial

European heart journal, 2011-04, Vol.32 (7), p.820-828

2011

Volltextzugriff (PDF)

Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors

Kidney international, 2016-09, Vol.90 (3), p.696-704

2016

Volltextzugriff (PDF)

Effects of Veverimer on Serum Bicarbonate and Physical Function in Women with CKD: A Subgroup Analysis from a Randomized Controlled Trial: PO2612

Journal of the American Society of Nephrology, 2020-10, Vol.31 (10S), p.792-792

2020

Volltextzugriff (PDF)

No Adverse Effects of Veverimer on Volume Status or Blood Pressure in Patients with CKD and Metabolic Acidosis: PO2116

Journal of the American Society of Nephrology, 2020-10, Vol.31 (10S), p.649-650

2020

Volltextzugriff (PDF)

Effects of Veverimer on Serum Bicarbonate and Physical Function in Patients with Diabetes and CKD: Subgroup Analysis from a Randomized Trial: PO1033

Journal of the American Society of Nephrology, 2020-10, Vol.31 (10S), p.352-353

2020

Volltextzugriff (PDF)

Effects of Veverimer on Serum Bicarbonate and Physical Function in Elderly Patients with Metabolic Acidosis in CKD: PO1685

Journal of the American Society of Nephrology, 2020-10, Vol.31 (10S), p.531-531

2020

Volltextzugriff (PDF)

Assessment of the Potential for Veverimer Drug-Drug Interactions

Drug metabolism and disposition, 2021-07, Vol.49 (7), p.490-500

2021

Volltextzugriff (PDF)

VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis

Journal of the American Society of Nephrology, 2024-03, Vol.35 (3), p.311-320

2024

Volltextzugriff (PDF)

P0001EFFECTS OF VEVERIMER ON SERUM BICARBONATE AND PHYSICAL FUNCTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND METABOLIC ACIDOSIS ARE INDEPENDENT OF ALBUMINURIA: SUBGROUP ANALYSES FROM A RANDOMIZED TRIAL

Nephrology, dialysis, transplantation, 2020-06, Vol.35 (Supplement_3)

2020

Volltextzugriff (PDF)

Evaluation of Veverimer Drug Interaction Potential: PO2373

Journal of the American Society of Nephrology, 2020-10, Vol.31 (10S), p.721-721

2020

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(43)

Sprache

Englisch
(43)

Erscheinungsjahr

n.n

Thema

Science & Technology
(21)
Life Sciences & Biomedicine
(20)
Humans
(15)
Female
(14)
Male
(14)
Middle Aged
(11)
Aged
(10)
Cardiovascular
(8)
Double-Blind Method
(8)
Renal Insufficiency, Chronic - Complications
(8)
Animals
(7)
Acidosis - Drug Therapy
(6)
Acidosis - Etiology
(6)
Chronic Kidney Disease
(6)
Polymers - Therapeutic Use
(6)
Adult
(5)
Biochemistry & Molecular Biology
(5)
Cell Biology
(5)
Molecular Sequence Data
(5)
Polymers - Adverse Effects
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors

Effects of Varespladib Methyl on Biomarkers and Major Cardiovascular Events in Acute Coronary Syndrome Patients

Nitric Oxide Negatively Regulates Mammalian Adult Neurogenesis

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

Essential function of nitric oxide synthase in Drosophila

Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial

Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension

The Drosophila Nitric-oxide Synthase Gene (dNOS) Encodes a Family of Proteins That Can Modulate NOS Activity by Acting as Dominant Negative Regulators

Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors

Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD

Action of Veverimer on Gastrointestinal Acid Binding Is Not Affected by Omeprazole: PO2374

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia

noxin, a Novel Stress-Induced Gene Involved in Cell Cycle and Apoptosis

Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial

Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors

Effects of Veverimer on Serum Bicarbonate and Physical Function in Women with CKD: A Subgroup Analysis from a Randomized Controlled Trial: PO2612

No Adverse Effects of Veverimer on Volume Status or Blood Pressure in Patients with CKD and Metabolic Acidosis: PO2116

Effects of Veverimer on Serum Bicarbonate and Physical Function in Patients with Diabetes and CKD: Subgroup Analysis from a Randomized Trial: PO1033

Effects of Veverimer on Serum Bicarbonate and Physical Function in Elderly Patients with Metabolic Acidosis in CKD: PO1685

Assessment of the Potential for Veverimer Drug-Drug Interactions

VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis

P0001EFFECTS OF VEVERIMER ON SERUM BICARBONATE AND PHYSICAL FUNCTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND METABOLIC ACIDOSIS ARE INDEPENDENT OF ALBUMINURIA: SUBGROUP ANALYSES FROM A RANDOMIZED TRIAL

Evaluation of Veverimer Drug Interaction Potential: PO2373

Suchergebnisse filtern